Genetically determined deficiency of the lactase enzyme in adults (primary hypolactasia) is a recessive trait. As shown earlier, in some European populations primary hypolactasia is determined by carrying the CC genotype at the single-nucleotide polymorphism (SNP) LCT*С/T-13910. In this work allele and genotype frequencies were estimated for the single-nucleotide polymorphism (SNP) LCT*C/ T-13910 in 7 samples (346 individuals in total), representing Eurasian populations (Saami, Mari, Russians from the Volga-Ural Area, Kazakhs, Uyghurs, Buriats, Arabs). For part of these groups and for some of the earlier studied groups the frequencies of the CC genotype are similar to the epidemiological-clinical data on hypolactasia frequency reported for respective or closely located populations (in Russians, Ukrainians, Byelorussians, Kola Saami, Mari, Komi-Permyaks, Udmurts, Pamir Mountain dwellers, and in Chukchi, Iranians and Arabs). For the Asian populations, the data are contradictory, and evaluation of genetic determination of hypolactasia in these populations requires further studies of larger samples. Considering association of primary hypolactasia with CC genotype in the Russian sample found by us earlier, the obtained results point that the CC genotype at SNP LCT*C/ T-13910 is the main genetic determinant of primary hypolactasia for populations of the European part of Russia.
The purpose of the study is to analyze the oncoepidemiological situation in the vicinity of nuclear industry and nuclear power plants. Materials and methods of the study. The main materials of the study were the data of official medical statistics for 2012-2018 on the incidence of malignant neoplasms and mortality from them: the contingent of medical treatment organizations of FMBA of Russia in 10 closed administrative-territorial formations of Rosatom State Corporation — a research sample; total contingent served by medical treatment organizations of FMBA of Russia — data of the Federal Center for Extreme Problems Information Technology of FMBA of Russia; population of Russian Federation as a whole. An in-depth analysis of the morbidity and mortality from malignant neoplasms among employees of enterprises and the population served by medical treatment organizations of FMBA of Russia was performed using data from the Branch Cancer Registry of FMBA of Russia. Results of the study and their analysis. According to the results of the analysis an increase in the incidence of malignant neoplasms was observed in medical treatment organizations of the Federal Medical and Biological Agency of Russia in closed administrative territorial formations, in all medical treatment organizations of the Federal Medical and Biological Agency of Russia, and in the Russian Federation as a whole. In 2012-2018 the incidence of malignant neoplasms (per 100,000 population) was: in closed administrative territorial entities — 412.4 and 526.6 respectively; in all medical treatment institutions of FMBA of Russia — 328.4 and 390.1; in the Russian Federation as a whole — 367.3 and 425.5 respectively. Analysis of mortality rates from malignant neoplasms showed that in all medical treatment institutions of the Federal Medical and Biomedical Agency of Russia the mortality rate from malignant neoplasms (per 100 thousand population) in this time interval was 149.1 and 167.9 persons respectively, which is significantly lower than the all-Russian rates of 201.0 and 200.0 persons respectively. Mortality from malignant neoplasms in closed administrative territorial units amounted to 220.1 and 257.3 persons respectively, which exceeds both all medical treatment institutions of the Federal Medical and Biological Agency and the Russian Federation as a whole.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.